Skip to content

A double-blind, randomised, placebo-controlled interventional study to evaluate the effect of orally-dosed herbal extract, Testofen (Trigonella foenum-graecum) on muscle strength, endurance and body composition in men aged between 25 and 45 years.

A double-blind, randomised, placebo-controlled interventional study to evaluate the effect of orally-dosed herbal extract, Testofen (Trigonella foenum-graecum) on muscle strength, endurance and body composition in men aged between 25 and 45 years.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000938404
Enrollment
138
Registered
2016-07-15
Start date
2016-08-02
Completion date
2017-10-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a double-blind, randomised, placebo-controlled interventional study to evaluate the effect of orally-dosed herbal extract, Testofen (Trigonella foenum-graecum) on muscle strength, endurance and body composition in men aged between 25 and 45 years.

Interventions

The investigational product is an ARTG listed (Aust L 187766) commercially available capsule-form herbal medicine containing 300mg Trigonella foenum- graecum (Fenugreek) seed extract. The daily dose will be 1 capsule taken in the morning and evening (total 2 capsules per day) for a period of 8 weeks. Active ingredient: Trigonella foenum-graecum extract 300mg equivalent to dry seed 9.9g Excipient ingredients: Maltodextrin All participants are provided with a bottle of the product (active or pl

The investigational product is an ARTG listed (Aust L 187766) commercially available capsule-form herbal medicine containing 300mg Trigonella foenum- graecum (Fenugreek) seed extract. The daily dose will be 1 capsule taken in the morning and evening (total 2 capsules per day) for a period of 8 weeks. Active ingredient: Trigonella foenum-graecum extract 300mg equivalent to dry seed 9.9g Excipient ingredients: Maltodextrin All participants are provided with a bottle of the product (active or placebo) and be asked to complete 3 set training sessions weekly. Participants will undertake muscle strength testing at baseline, week 4 and week 8. Participants will undertake a body composition assessment at baseline and week 8. At baseline and week 8, the following questionnaires will be completed 36-item Short Form Health Survey and Food frequency diary. The following blood tests will be performed at baseline and week 8 to assess the effect of the product and for safety measures, liver function, Bilirubin, full blood count, creatinine/eGFR, Homocysteine, glutathione, malonyldialdehyde, reactive oxygen species, c-reactive protein, blood glucose and tolerance, cortisol and testosterone. Adherence to the intervention will be monitored by drug tablet return. Exercise Schedule Each exercise session will run for approximately 15mins and involves: 1. a warm-up/light stretch and mobility phase (approx 5 mins) 2. targeted resistance phase (changing on a weekly basis) (approx 10-15mins) 3. cool down and mobility stretch (approx 5 mins); and 4. recovery phase (in own time) Participants undertaken 3 exercise training sessions weekly and at baseline, week 4 and week 8 a strength and exercise performance assessment. In the first week there will be a strong emphasis on technique and not doing any more or less than what is given. Furthermore, a clear understanding of any previous injuries or restrictions anyone might have. As this week goes on, exercises will become more intense and depending each participants ability, the exercise will be modified to become more challenging. Types of exercise range from core (eg sit-ups), weights (eg one arm rows, kettle bell swings), body strength (eg lunges, push ups). Participation at each training session will be signed off. The exercise sessions are led by a qualified personal trainer and overseen by a Exercise Physiologist.

Sponsors

Integrated Health Global Pty Ltd
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
Male
Age
25 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

Males aged 25-45 years BMI 18.5-29.9 – Participants to be in the healthy to overweight range Not currently undertaking resistance training exercise Lightly trained – undertaking low impact cardiovascular exercise including but not limited to cycling, swimming and walking not more than 5 x weekly Written informed consent from the participant Willing to participate in an exercise program 3 x per week

Exclusion criteria

Currently undertaking resistance training exercise Clinically significant medical conditions including, but not limited to, cardiovascular, neurological, psychiatric, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haemotogical abnormalities that are uncontrolled. Consumption of any dietary supplements in the last 3 months Known hypersensitivity to herbal drugs/nutritional supplement/ foods Substantial alcohol consumption (21 drinks per week for men), drug use, or other confounding conditions Patients on prolonged (approximately 6 weeks) medication with corticosteroids, antidepressants, anticholinergics etc. or any other drugs that may have an influence on the outcome of the study. Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Participants who have completed participation in any other clinical trial during past 6 months History of orthopaedic injuries or surgery in the past 6 months Females Active smokers

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 10, 2026